• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Soleno Therapeutics Inc.

    8/7/24 4:54:05 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $SLNO alert in real time by email
    S-8 1 d866711ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on August 7, 2024

    Registration No. 333-   

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

     

     

    SOLENO THERAPEUTICS, INC.

    (Exact name of Registrant as specified in its charter)

     

     

     

    Delaware   77-0523891
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification Number)

     

     

    203 Redwood Shores Pkwy, Suite 500

    Redwood City, CA 94065

    (Address of principal executive offices, including zip code)

     

     

    Amended and Restated 2014 Equity Incentive Plan

    (Full title of the plan)

     

     

    Anish Bhatnagar

    Chief Executive Officer

    Soleno Therapeutics, Inc.

    203 Redwood Shores Pkwy, Suite 500

    Redwood City, CA 94065

    (Name and address of agent for service)

     

     

    (650) 213-8444

    (Telephone number, including area code, of agent for service)

     

     

    Copies to:

    Elton Satusky

    Jesse Schumaker

    Wilson Sonsini Goodrich & Rosati

    Professional Corporation

    650 Page Mill Road

    Palo Alto, California 94304

    (650) 493-9300

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act (Check one)

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    EXPLANATORY NOTE

    This Registration Statement on Form S-8 (the “Registration Statement”) registers 2,000,000 shares of Common Stock (“Shares”) of Soleno Therapeutics, Inc. (the “Registrant”) reserved for issuance under the Registrant’s Amended and Restated 2014 Equity Incentive Plan (the “2014 Plan”). The increase of 2,000,000 Shares was approved by the Company’s stockholders on June 6, 2024.


    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”), and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the equity benefit plans covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act.

    Item 3. Incorporation of Documents by Reference.

    The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed with the Securities and Exchange Commission (the “Commission”):

     

      (1)

    The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2023 (the “Annual Report”), as filed with the Commission on March 7, 2024 pursuant to Sections 13 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”);

     

      (2)

    The Registrant’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2024 and June 30, 2024, as filed with the Commission on May  9, 2024 and August 7, 2024, respectively, pursuant to Sections 13 or 15(d) of the Exchange Act;

     

      (3)

    All other reports filed with the Commission pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Annual Report; and

     

      (4)

    The description of the Registrant’s common stock contained in the Exhibit 4.29 to the Registrant’s Annual Report, filed with the Commission on March 7, 2024.

    All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Under no circumstances will any information furnished under current items 2.02 or 7.01 of Form 8-K be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.

    Item 4. Description of Securities.

    Not applicable.

    Item 5. Interests of Named Experts and Counsel.

    Not applicable.

    Item 6. Indemnification of Directors and Officers.

    Section 145 of the Delaware General Corporation Law authorizes a corporation’s board of directors to grant, and authorizes a court to award, indemnity to officers, directors and other corporate agents.


    As permitted by Section 102(b)(7) of the Delaware General Corporation Law, the Registrant’s amended and restated certificate of incorporation includes provisions that eliminate the personal liability of its directors for monetary damages for breach of their fiduciary duty as directors, excluding liability for any breach of the duty of loyalty.

    In addition, as permitted by Section 145 of the Delaware General Corporation Law, the amended and restated certificate of incorporation and amended and restated bylaws of the Registrant provide that:

     

      •  

    The Registrant shall indemnify its directors and officers for serving the Registrant in those capacities or for serving other business enterprises at the Registrant’s request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the Registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person’s conduct was unlawful.

     

      •  

    The Registrant may, in its discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law.

     

      •  

    The Registrant is required to advance expenses, as incurred, to its directors and officers in connection with defending a proceeding, except that such director or officer shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification.

     

      •  

    The Registrant will not be obligated pursuant to the amended and restated bylaws to indemnify a person with respect to proceedings initiated by that person, except with respect to proceedings authorized by the Registrant’s board of directors or brought to enforce a right to indemnification.

     

      •  

    The rights conferred in the amended and restated certificate of incorporation and amended and restated bylaws are not exclusive, and the Registrant is authorized to enter into indemnification agreements with its directors, officers, employees and agents and to obtain insurance to indemnify such persons.

     

      •  

    The Registrant may not retroactively amend the bylaw provisions to reduce its indemnification obligations to directors, officers, employees and agents.

    The Registrant has entered into separate indemnification agreements with each of its directors and officers that provide the maximum indemnity allowed to directors and executive officers by Section 145 of the Delaware General Corporation Law and also to provide for certain additional procedural protections. The Registrant also maintains directors and officers insurance to insure such persons against certain liabilities.

    These indemnification provisions and the indemnification agreements entered into between the Registrant and its officers and directors may be sufficiently broad to permit indemnification of the Registrant’s officers and directors for liabilities (including reimbursement of expenses incurred) arising under the Securities Act.

    See also the undertakings set out in response to Item 9 herein.

    Item 7. Exemption from Registration Claimed.

    Not applicable.


    Item 8. Exhibits.

     

              Incorporated by Reference  
    Exhibit
    Number
      

    Description

       Form      File No.      Exhibit      Filing Date  
      4.1    Form of the Registrant’s common stock certificate      S-1/A        333-196635        4.1        08/05/2014  
      4.2    Amended and Restated 2014 Equity Incentive Plan and forms of agreement thereunder      8-K        001-36593        10.1        06/06/2024  
      5.1    Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation (contained in Exhibit 5.1 hereto)            
     23.1    Consent of Marcum LLP, Independent Registered Public Accounting Firm (contained in Exhibit 23.1 hereto)            
     23.2    Consent of Wilson Sonsini Goodrich & Rosati, Professional Corporation (contained in Exhibit 5.1 hereto)            
     24.1    Power of Attorney (contained on signature page hereto)            
    107.1    Calculation of Filing Fees Table            

    Item 9. Undertakings.

     

    A.

    The undersigned Registrant hereby undertakes:

     

      (1)

    To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

      (i)

    To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

      (ii)

    To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement.

    Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

     

      (iii)

    To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement.

    Provided, however, that paragraphs (A)(1)(i) and (A)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

     

      (2)

    That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

      (3)

    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    B.

    The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.


    C.

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Redwood City, California, on the 7th day of August, 2024.

     

    SOLENO THERAPEUTICS, INC.
    By:   /s/ Anish Bhatnagar
      Anish Bhatnagar
      Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Anish Bhatnagar as his true and lawful attorney-in-fact and agent with full power of substitution, for him in any and all capacities, to sign any and all amendments to this registration statement on Form S-8 (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact, proxy and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact, proxy and agent, or his substitute, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this registration statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

      

    Title

     

    Date

    /s/ Anish Bhatnagar

    Anish Bhatnagar

       President, Chief Executive Officer and Director
    (Principal Executive Officer)
      August 7, 2024

    /s/ James Mackaness

    James Mackaness

       Chief Financial Officer
    (Principal Financial and Accounting Officer)
      August 7, 2024

    /s/ Ernest Mario

    Ernest Mario

       Chairman   August 7, 2024

    /s/ William G. Harris

    William G. Harris

       Director   August 7, 2024

    /s/ Matthew Pauls

    Matthew Pauls

       Director   August 7, 2024

    /s/ Andrew Sinclair

    Andrew Sinclair

       Director   August 7, 2024

    /s/ Birgitte Volck

    Birgitte Volck

       Director   August 7, 2024
    Get the next $SLNO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SLNO

    DatePrice TargetRatingAnalyst
    11/18/2025$75.00Outperform
    Wolfe Research
    10/7/2025$125.00Buy
    Goldman
    8/20/2025$123.00Overweight
    Wells Fargo
    6/23/2025$110.00Buy
    TD Cowen
    3/5/2025$74.00Buy
    Stifel
    12/2/2024$74.00Buy
    Stifel
    12/2/2024$72.00Outperform
    Robert W. Baird
    9/3/2024$70.00Buy
    H.C. Wainwright
    More analyst ratings

    $SLNO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Soleno Therapeutics with a new price target

    Wolfe Research initiated coverage of Soleno Therapeutics with a rating of Outperform and set a new price target of $75.00

    11/18/25 8:27:59 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Goldman initiated coverage on Soleno Therapeutics with a new price target

    Goldman initiated coverage of Soleno Therapeutics with a rating of Buy and set a new price target of $125.00

    10/7/25 9:49:14 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Wells Fargo initiated coverage on Soleno Therapeutics with a new price target

    Wells Fargo initiated coverage of Soleno Therapeutics with a rating of Overweight and set a new price target of $123.00

    8/20/25 9:01:56 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $SLNO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Perceptive Advisors Llc bought $15,113,916 worth of shares (866,789 units at $17.44) (SEC Form 4)

    4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

    9/28/23 3:45:22 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $SLNO
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Soleno Therapeutics Inc.

    SCHEDULE 13G - SOLENO THERAPEUTICS INC (0001484565) (Subject)

    2/10/26 11:17:43 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 8-K filed by Soleno Therapeutics Inc.

    8-K - SOLENO THERAPEUTICS INC (0001484565) (Filer)

    1/23/26 5:00:19 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Soleno Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - SOLENO THERAPEUTICS INC (0001484565) (Filer)

    1/12/26 8:51:13 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $SLNO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $SLNO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Soleno Therapeutics to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026, at 4:30 PM ET

    REDWOOD CITY, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its fourth quarter and full-year 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Wednesday, February 25, 2026. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Wednesday, February 25, 2026Time:4:30 PM Eastern TimeUnited States:1-800-717-1738Internation

    2/11/26 8:00:00 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Soleno Therapeutics to Participate in Upcoming Conferences

    REDWOOD CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in February and March: Guggenheim Emerging Outlook: Biotech Summit 2026Presentation Date: Thursday, February 12, 2026 at 11:30 AM ETPresentation Format: Fireside ChatWebcast: Here Oppenheimer 36th Annual Healthcare Life Sciences ConferencePresentation Date: Thursday, February 26, 2026 at 10:00 AM ETPresentation Format: Company presentation TD Cowen 46th Annual Health Care Conference Presentation Date: Wednesday

    1/29/26 8:00:00 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SLNO Investors: Contact Kirby McInerney LLP About Investigation into Soleno Therapeutics, Inc.

    The law firm of Kirby McInerney LLP continues its investigation on behalf of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ:SLNO) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On August 15, 2025, Scorpion Capital published a report that described Soleno's only product, Vykat XR, as overpriced and potentially unsafe for children. On this news, the price of Soleno shares declined by $5.73 per share, or approximately 7.41%, from $77.36 per share on August 14, 2025 to close at $71.64 on August 15, 2025.

    1/12/26 6:00:00 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Officer Yen Kristen was granted 10,400 shares, increasing direct ownership by 38% to 37,639 units (SEC Form 4)

    4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

    1/23/26 6:08:14 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Business Officer Norrett Kevin was granted 3,500 shares, increasing direct ownership by 24% to 17,786 units (SEC Form 4)

    4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

    1/23/26 6:07:08 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Commercial Officer Manning Meredith was granted 28,600 shares, increasing direct ownership by 66% to 72,029 units (SEC Form 4)

    4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

    1/23/26 6:06:06 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $SLNO
    Leadership Updates

    Live Leadership Updates

    View All

    Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn to its Board of Directors

    REDWOOD CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of biopharmaceutical finance veteran Mark W. Hahn as an independent director to its Board of Directors and a member of its Audit Committee. Mr. Hahn brings to Soleno's Board nearly 30 years of CFO-level experience and has played a key role in numerous successful product launches, financings, and M&A transactions within the life sciences sector. With the addition of Mr. Hahn, the Soleno Board increases to seven seats.    "I am very pleased to welcome Mark to the

    10/13/25 8:00:00 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Soleno Therapeutics Set to Join Russell 3000® Index

    REDWOOD CITY, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024. "Inclusion in the Russell indexes is a significant milestone and reflects the meaningful progress Soleno has made in advancing our lead candidate DCCR (diazoxide choline) extended-release ta

    6/4/24 8:00:00 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Soleno Therapeutics Strengthens Leadership Team with Key Appointments

    REDWOOD CITY, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointments of Meredith Manning, M.B.A as Chief Commercial Officer, Dairine Dempsey, Ph.D. as Vice President, Europe and Lauren Budesheim, M.S. as Vice President of Human Resources. The Company also announced the appointment of key advisors with Shamim Ruff, M.S. joining as Chair of the Development Advisory Board and James (Jim) Geraghty, J.D., M.S. as a Board Advisor. "As we move into the next phase of Soleno's growth, we are delighted to welcome seasone

    1/24/24 8:00:00 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $SLNO
    Financials

    Live finance-specific insights

    View All

    Soleno Therapeutics to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026, at 4:30 PM ET

    REDWOOD CITY, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its fourth quarter and full-year 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Wednesday, February 25, 2026. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Wednesday, February 25, 2026Time:4:30 PM Eastern TimeUnited States:1-800-717-1738Internation

    2/11/26 8:00:00 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Soleno Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on U.S. Launch of VYKAT(TM) XR

    REDWOOD CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today reported financial results for the third quarter ended September 30, 2025 and provided an update on the U.S. launch of VYKATTM XR. Third Quarter 2025 and Recent Corporate Highlights Revenue, net, from the sale of VYKAT XR for the three months ended September 30, 2025 was $66.0 million and the Company achieved profitability with positive net income of $26.0 million for the third quarter.From approval on March 26, 2025 through September 30, 2025, Soleno reports: 1,043 patient start form

    11/4/25 4:01:00 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Soleno Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025, at 4:30 PM ET

    REDWOOD CITY, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its third quarter 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Tuesday, November 4, 2025. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Tuesday, November 4, 2025Time:4:30 PM Eastern TimeUnited States:1-800-717-1738International:1-646-307-1865Conf

    10/21/25 8:00:00 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $SLNO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Soleno Therapeutics Inc.

    SC 13D/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

    11/19/24 9:44:27 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13D/A filed by Soleno Therapeutics Inc.

    SC 13D/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

    11/14/24 4:30:58 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Soleno Therapeutics Inc.

    SC 13G/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

    11/14/24 12:51:18 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care